Kbi-098 【TRENDING】

: A prominent small molecule being developed by BioVersys in collaboration with GSK to treat tuberculosis. It is designed to overcome antibiotic resistance and is currently in Phase 2 clinical trials.

"KBI" is the standard abbreviation for the . KBI-098

: A major contract development and manufacturing organization (CDMO) that specializes in biologics. While they manage numerous development programs, "KBI-098" does not appear as a standard public designation for their current internal pipeline or client-facing projects. 2. Criminal Justice and Public Safety : A prominent small molecule being developed by

There is no definitive widely recognized entity, chemical compound, or project known as . or project known as .